文献速递痛风与晶体性关节病

外周血管DECT尿酸编码斑块的鉴定与特征:VASCURATE研究

Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study.
PubMed 文献 · Semin Arthritis Rheum · 2021-06-20

前瞻性纳入126例痛风患者和26例对照,用双能CT(DECT)评估膝关节动脉中编码为单钠尿酸盐(MSU)沉积的血管斑块。血管MSU编码斑块在痛风与对照中患病率相当,与动脉钙化强相关而与软组织MSU沉积无关,随访中虽有效降尿酸治疗仍保持稳定。

要点

  • DECT血管MSU编码斑块在痛风与对照中患病率相当。
  • 血管MSU编码斑块与动脉钙化强相关,与软组织MSU沉积无关。
  • 有效降尿酸治疗不改变血管MSU编码斑块。

核心结论

  • DECT外周动脉MSU编码斑块与钙化强相关,可能并非真正MSU晶体沉积,不应作为痛风管理的主要靶标。

研究设计与样本

  • 前瞻性纳入疑似晶体关节病患者进入CRYSTALILLE起始队列,基线行膝与踝/足DECT扫描。
  • 共研究126例痛风患者和26例对照,其中17例未治痛风患者进入随访。
  • 随访患者启动达标降尿酸治疗,在6和12个月重复DECT并测血尿酸。

主要发现

  • DECT血管MSU编码斑块患病率在痛风患者为24.6%,对照为23.1%(p=0.87)。
  • 血管MSU编码斑块与并存动脉钙化强相关(p<0.001),与软组织MSU沉积无关。
  • 血管MSU编码斑块的DECT参数与对照血管、对照软组织及痛风石存在特定差异。
  • 随访中血管MSU编码斑块保持稳定(p=0.64),而有效降尿酸治疗降低血尿酸和软组织MSU体积(p<0.001)。

关键数值与推荐

  • DECT血管MSU编码斑块患病率:痛风24.6% vs 对照23.1%(p=0.87)。
  • 血管MSU编码斑块与动脉钙化相关p<0.001,与软组织MSU沉积无关。
  • 随访中血管MSU编码斑块稳定p=0.64,血尿酸和软组织MSU体积下降p<0.001。

临床怎么用

  • 解读外周动脉DECT MSU编码斑块时应考虑其与钙化相关,避免误判为活动性MSU沉积。
  • 痛风管理中不应将血管MSU编码斑块作为主要治疗靶标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize peripheral vascular plaques color-coded as monosodium urate (MSU) deposition by dual-energy computed tomography (DECT) and assess their association with the overall soft-tissue MSU crystal burden. METHODS: Patients with suspected crystal arthropathies were prospectively included in the CRYSTALILLE inception cohort to undergo baseline knees and ankles/feet DECT scans; treatment-naive gout patients initiating treat-to-target urate-lowering therapy (ULT) underwent repeated DECT scans with concomitant serum urate level measurements at 6 and 12 months. We determined the prevalence of DECT-based vascular MSU-coded plaques in knee arteries, and assessed their association with the overall DECT volumes of soft-tissue MSU crystal deposition and coexistence of arterial calcifications. DECT attenuation parameters of vascular MSU-coded plaques were compared with dense calcified plaques, control vessels, control soft tissues, and tophi. RESULTS: We investigated 126 gout patients and 26 controls; 17 ULT-naive gout patients were included in the follow-up study. The prevalence of DECT-based vascular MSU-coded plaques was comparable in gout patients (24.6%) and controls (23.1%; p=0.87). Vascular MSU-coded plaques were strongly associated with coexisting arterial calcifications (p<0.001), but not with soft-tissue MSU deposition. Characterization of vascular MSU-coded plaques revealed specific differences in DECT parameters compared with control vessels, control soft tissues, and tophi. During follow-up, vascular MSU-coded plaques remained stable despite effective ULT (p=0.64), which decreased both serum urate levels and soft-tissue MSU volumes (p<0.001). CONCLUSION: Our findings suggest that DECT-based MSU-coded plaques in peripheral arteries are strongly associated with calcifications and may not reflect genuine MSU crystal deposition. Such findings should therefore not be a primary target when managing gout patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pascart T, Carpentier P, Choi HK, et al. Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study. Semin Arthritis Rheum. 2021. PMID: 34198148. doi:10.1016/j.semarthrit.2021.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。